All In MedTech

FDA Clearance Tracker · P080030-S012

GLAUKOS ISTENT TRABECULAR MICRO-BYPASS STENT SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 16, 2014 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 16, 2014

Approved

Time to decision

77 days

Received Sep 30, 2014. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P080030-S012
Device name
GLAUKOS ISTENT TRABECULAR MICRO-BYPASS STENT SYSTEM
Applicant location
Laguna Hills, CA
Received
Sep 30, 2014
Decided
Dec 16, 2014
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P080030

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code OGO

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE MODIFICATIONS TO THE MODEL GTS100I INSERTER AND STENT, WHICH COMPRISE THE ISTENT TRABECULAR MICRO-BYPASS STENT SYSTEM. THE MODIFICATIONS INCLUDE THEFOLLOWING:1) CHANGES TO THE INSERTER TO INCLUDE:A) A LARGER SLEEVE DIAMETER FOR INCREASED RIGIDITY OF THE SLIDE ASSEMBLY;B) AN INCREASE IN THE INTERNAL SPRING FORCE; C) A CHANGE TO THE GEOMETRY AND EXTENSION OF THE GRASPING TINES ON THE END OF THE SLOTTED TUBE; D) A RE-DESIGN OF THE RELEASE BUTTON ROCKER MECHANISM; AND E) COLOR CHANGES TO TWO OUTER INSERTER COMPONENTS (REAR HOUSING AND TRIGGER BUTTON).2) CHANGES TO THE STENT TO INCLUDE:A) AN INCREASE IN THE WALL THICKNESS OF THE SNORKEL BY TIGHTENING THE DIMENSIONAL TOLERANCE FROM A RANGE 0.155 TO 0.200 MM TO A RANGE OF 0.170 TO 0.200 MM; AND B) REMOVAL OF THE STENTING HEIGHT PARAMETER FROM THE FINISHED DEVICE DRAWINGS 10-0018 AND 10-0019 AS A CRITICAL DIMENSION.3) CHANGES TO THE STENT SYSTEM TO INCLUDE:A) A CHANGE FROM STERILIZATION FOLLOWING PRIMARY PACKAGING TO STERILIZATION FOLLOWING FINAL PACKAGING; AND B) ELIMINATION OF THE IN-PROCESS GRIP FORCE TESTING STEP.

Source documents

Other decisions for Glaukos Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

1 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.